Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Grünenthal Developed Novel Resiniferatoxin for the Treatment of Knee Osteoarthritis

Grünenthal developed novel resiniferatoxin (RTX), for the pain associated with osteoarthritis (OA) of the knee which is currently undergoing clinical Phase III development.

Resiniferatoxin, is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. By administering it as an intra-articular injection directly into the knee joint, it aims to defunctionalise TRPV1-expressing nociceptors, providing long-lasting pain relief for patients with knee osteoarthritis. Preliminary data showed a significant analgesic effect and functional improvement compared to placebo with a favourable safety profile.

Millions of patients suffering from knee osteoarthritis eagerly await additional treatment options, as the disease currently lacks a cure. Resiniferatoxin holds promise as a potential solution to alleviate the pain associated with this condition.

Resiniferatoxin, if granted approval, holds promising potential as a non-opioid treatment option that can offer enduring pain relief and enhance the functioning of the affected joint. Additionally, it demonstrates a favourable safety profile, further adding to its value as a viable treatment alternative.

U.S. Food and Drug Administration (FDA) grants breakthrough designation for resiniferatoxin for the treatment of pain associated with knee osteoarthritis.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024